A New Generation Clinical Decision Support System

Seminar Date: 
Seminar Time: 
11am - 12pm
Seminar Location: 
5607 Baum Boulevard, Room 407A
Xia Jiang, PhD

Abstract: This talk is mainly about an introduction to the proposed research of a newly funded R01 grant titled “A New Generation Clinical Decision Support System.”

Critical clinical activities involve decision making. For both individual patients and for society at large, making good healthcare decisions is a paramount task. The objective of this research is to develop a novel decision support system that utilizes both the clinical features and the genomic profile of a breast cancer patient to assist the physician in integrating information about a specific patient (diagnostic subtype, tumor stage and grade, age, comorbidities) to make therapeutic plans for the patient.

Traditional clinical data are becoming increasingly available in electronic form. Unprecedentedly abundant genomic data are available to researchers as the results of advanced sequencing technologies such as next generation sequencing. Patient-specific genomic data are likely to become available for most patients in the foreseeable future. These sources of data provide significant opportunities for developing new generation clinical decision support systems that can achieve substantial progress over what is currently possible. However, the sheer magnitude of the number of variables in these data (often in the millions) presents formidable computational and modeling challenges. Also, integrating the heterogeneous information in multiple clinical datasets and genomic datasets presents an arduous challenge.

Breast cancer is the commonest cancer among women. Various breast cancer subtypes have been defined which, along with tumor stage, predict response to therapy and survival, albeit imperfectly. For example, HER2-amplified breast cancer is a subtype with poor prognosis, and therapy with an antibody to HER2 (Herceptin) has vastly improved the survival of such patients. Although Herceptin is used in the therapy of all patients with HER2-amplified tumors, only some respond. Also, it is expensive and can cause cardiac toxicity. So, it is important to give it only to patients benefiting from it. Studies show thousands of genes are associated with subtype and prognosis of breast cancer, and particular allele combinations may usefully guide the selection of effective treatment. The proposed system will amass all this genomic information and combine it with clinical information and therefore holds promise to provide accurate classification and treatment choices. It will build on previous results of the investigators in using Bayesian Network to learn from high-dimensional data sets.